Tuhura Biosciences與Kineta公司進入排他性和首要出價協議，涉及Kva

快訊 · 07/08 18:30

Tuhura Biosciences Enters Into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s Kva12123 Novel Anti-Vista Checkpoint Inhibitor

Tuhura Biosciences與Kineta公司進入排他性和首要出價協議，涉及Kva12123新型抗Vista檢查點抑制劑。